Today's Daily Dose brings you news about Bristol Myers' regulatory catalyst; Liquidia's pulmonary arterial hypertension drug candidate; Moleculin Biotech joining the bandwagon of COVID-19 drug development; MediciNova initiating a clinical trial of MN-166 for acute respiratory distress syndrome (ARDS) caused by COVID-19 and FDA approval of Pfizer's BRAFTOVI for yet another indication.
from RTT - Biotech https://ift.tt/3c7NBUh
via IFTTT
No comments:
Post a Comment